Association between Sarcopenia and Metabolic Syndrome in Middle-Aged and Older Non-Obese Adults: A Systematic Review and Meta-Analysis.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
metabolic syndrome 11 endocrinologydiseases
obesity 6 endocrinologydiseases

There are not enough annotations found in this document to create the proximity graph.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Select Disease Character Offset Disease Term Instance
metabolic syndrome 575 (epub): 3/2018Publication date (collection): 3/2018AbstractThe associations between sarcopenia and metabolic syndrome (MetS) in non-obese middle-aged and older adults remain controversial. Thus, this meta-analysis aimed
metabolic syndrome 3668 cardiovascular morbidity and mortality, as well as all-cause mortality [[8],[9],[10]]. The prevalence of metabolic syndrome is increasing worldwide. The unadjusted MetS prevalence was 34.1% among US adults (aged ≥ 20 years)
metabolic syndrome 5929 Science databases from inception to 11 May 2017. The keywords used in search were those referring to metabolic syndrome (metabolic syndrome X, metabolic syndrome, Plurimetabolic syndrome, Reaven syndrome, syndrome X, dysmetabolic
metabolic syndrome 5949 from inception to 11 May 2017. The keywords used in search were those referring to metabolic syndrome ( metabolic syndrome X, metabolic syndrome, Plurimetabolic syndrome, Reaven syndrome, syndrome X, dysmetabolic syndrome X,
metabolic syndrome 5971 2017. The keywords used in search were those referring to metabolic syndrome (metabolic syndrome X, metabolic syndrome , Plurimetabolic syndrome, Reaven syndrome, syndrome X, dysmetabolic syndrome X, cardiovascular syndrome
metabolic syndrome 5996 in search were those referring to metabolic syndrome (metabolic syndrome X, metabolic syndrome, Pluri metabolic syndrome , Reaven syndrome, syndrome X, dysmetabolic syndrome X, cardiovascular syndrome and insulin resistance
metabolic syndrome 6048 (metabolic syndrome X, metabolic syndrome, Plurimetabolic syndrome, Reaven syndrome, syndrome X, dys metabolic syndrome X, cardiovascular syndrome and insulin resistance syndrome) and sarcopenia (sarcopenia, sarcopenic obesity,
metabolic syndrome 27526 bioelectric impedance analysis; BMI, body mass index; DXA, dual energy X­ray absorptiometry; MetS, metabolic syndrome ; N/A, not available; NCEP-ATPIII, the National Cholesterol Education Program Adult Treatment Panel III;
metabolic syndrome 27770 mass index; Wt, weight.nutrients-10-00364-t002_Table 2Table 2Meta-analysis results of prevalence of metabolic syndrome in middle-aged and older non-obese adults with or without sarcopenia.AnalysisNumber of StudiesNumber
metabolic syndrome 29090 (0.08–0.18)-Cohort size (n)0.0081n ≥ 200830,8000.27 (0.21–0.34)99%n < 20023540.08 (0.03–0.19)84%Notes: MetS, metabolic syndrome ; NCEP-ATPIII, National Cholesterol Education Program Adult Treatment Panel III; AHA/NHLBI/IDF, American
metabolic syndrome 30342 evaluationDivided by BMI111.92 (1.53–.41)78.9<0.001Adjustment for BMI22.01 (1.63–2.47)89.1<0.001Notes: MetS, metabolic syndrome ; NCEP-ATPIII, National Cholesterol Education Program Adult Treatment Panel III; AHA/NHLBI/IDF, American
obesity 3437 from sarcopenia [[2]]. Metabolic syndrome (MetS) is a cluster of metabolic abnormalities (abdominal obesity , high blood pressure, high blood glucose, and blood lipid abnormalities) that is associated with an
obesity 4552 and aging disease, sarcopenia is known to be associated with various metabolic disorders, including obesity [[13]], insulin resistance [[14]], diabetes [[15]], dyslipidemia [[16]], and hypertension [[17]]. Several
obesity 6166 X, cardiovascular syndrome and insulin resistance syndrome) and sarcopenia (sarcopenia, sarcopenic obesity , loss of skeletal muscle, loss of muscle mass and strength, and muscle wasting). Conference abstracts
obesity 21687 obese adults is unknown. Although MetS can be seen in non-obese individuals and develops independent of obesity , obesity always contributes to MetS-associated metabolic alterations [[47]]. To address these issues,
obesity 21696 is unknown. Although MetS can be seen in non-obese individuals and develops independent of obesity, obesity always contributes to MetS-associated metabolic alterations [[47]]. To address these issues, more studies
obesity 21862 alterations [[47]]. To address these issues, more studies with detailed data stratified by sex and sarcopenic obesity are needed.4.3. Strengths and LimitationsOur study had multiple strengths. First, our analysis focus

You must be authorized to submit a review.